In pancreatic ductal adenocarcinoma (PDAC) patients, an EV-associated expression of highly upregulated in liver cancer (HULC) long non-coding RNA (lncRNA) was demonstrated to perform even better than the already established circulating serum biomarkers carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) in terms of discriminating between cancer patients and non-PDAC controls [103]. The gene discussed is CEACAM5; the disease is pancreatic ductal adenocarcinoma.